<DOC>
	<DOCNO>NCT00595556</DOCNO>
	<brief_summary>This pilot study design examine potential efficacy tolerability zonisamide compare placebo treatment alcohol dependence .</brief_summary>
	<brief_title>Zonisamide v . Placebo Treatment Alcohol Dependence</brief_title>
	<detailed_description>Zonisamide antiepileptic medication similar clinical pharmacologic effect topiramate , medication demonstrate efficacy randomized clinical trial treatment alcoholism . Because zonisamide potentially well tolerate easy titrate outpatient set topiramate , may offer important clinical advantage treatment alcoholism . This small 12-week placebo-controlled pilot study examine tolerability potential efficacy anticipation large , placebo-controlled trial zonisamide treatment alcohol dependence . It randomize , double-blind trial zonisamide vs. placebo flexible dosage 100-500mg/day alcoholic receive ambulatory psychosocial treatment . Participants take part six individual Cognitive-Behavioral base therapy session , focus learn cop skill . Participants must endorse goal either cut drink non-hazardous level , abstinence .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>age 18 65 year , inclusive current Diagnostic &amp; Statistical Manual Mental Disorders 4th ed ( DSMIV ) alcohol dependence ( within past month ) 2 heavy drinking day per week period screen baseline ( define &gt; 4 standard drink per day male , &gt; 3 standard drink per day female ) able read eighth grade high level show evidence significant cognitive impairment woman childbearing potential ( i.e. , hysterectomy , bilateral oophorectomy , tubal ligation less two year postmenopausal ) , must nonlactating , practice reliable method birth control include barrier method ; negative serum pregnancy test prior initiation treatment willing provide sign , inform consent participate study current , clinically significant physical disease abnormality ( i.e. , neurologic , renal , rheumatologic , gastrointestinal , hematologic , pulmonary , endocrine , cardiovascular , hepatic , autoimmune disease , context study would represent risk subject , significant laboratory abnormality hepatic aminotransferase level great 300 % up limit normal direct bilirubin level 150 % upper limit normal ) basis medical history , physician examination , routine laboratory evaluation . Serum creatinine level &gt; 1.2 mg/dl also exclusionary . Other specific exclusionary disorder include : patient history renal calculus patient history hypersensitivity zonisamide sulfonamide , StevensJohnson Syndrome , penicillin allergy , history severe drug allergic reaction patient significant history systemic autoimmune disease lupus erythematosis , fibromyalgia , rheumatoid arthritis patient current blood dyscrasia history , exception remote history iron deficient anemia serious psychiatric illness ( i.e. , schizophrenia , bipolar disorder , severe psychotic major depression , panic disorder , substantial suicide violence risk ) basis history psychiatric examination current dependence opioids benzodiazepines sedative also exclusionary consider investigator clinically inappropriate study participation individual history seizure disorder could potentially increase risk experience seizure due drinking , individual also exclude participate another pharmacotherapy study past thirty day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Zonisamide</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Alcohol dependence</keyword>
	<keyword>anticonvulsant</keyword>
</DOC>